Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study
Sponsor: Centre Hospitalier Universitaire, Amiens
Summary
COVID-19 is causing a serious viral pandemic in terms of health and social impact. To date, no treatment has yet demonstrated Strong efficacy in treating the infectious disease (COVID-19). Pulmonary administration of Interferon (IFN) type I is a therapeutic strategy with high potential,due to higher local concentrations and minimal adverse effects. Type I interferons (including IFN-α and IFN-β) are antiviral defence cytokines and also have the potential to negatively modulate IFN Type II and IL-6 dependent cytokine storm, the latter being induced in the late forms of COVID-19. In vitro, IFN-β were more effective on COVID-19 than IFN-α. In existing preliminary studies, only patients receiving IFN type I modulators have a decrease in viral carriage and a rapid reversal. The purpose of this project is to assess in hospitalized patients with oxygen for COVID 19, the clinical efficacy on oxygen requirements of the addition of inhaled Interferon type I compared to the control arm .
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
74
Start Date
2020-09-20
Completion Date
2025-12
Last Updated
2025-11-19
Healthy Volunteers
No
Conditions
Interventions
inhaled type I interferon
The interventional arm includes inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. In phase B, maximum treatment duration is 8 days.
WFI water nebulization
The interventional arm includes a WFI water nebulization comparator.
Locations (7)
CH d'Abbeville
Abbeville, France
CHU Amiens
Amiens, France
CH Compiègne-Noyon
Compiègne, France
CH de l'Arrondissement de Montreuil-sur-mer
Rang-du-Fliers, France
CH de Saint-Quentin
Saint-Quentin, France
CH de Tourcoing
Tourcoing, France
CH de valenciennes
Valenciennes, France